Veradermics Posts $21 Million Loss as Male Hair-Loss Trials Turn Positive

The Tip Desk · November 12, 2026 · 4 min read

Cash, cash equivalents and marketable securities stood at $798.4 million as of September 30, 2026, a level the company said is expected to fund operations into 2030.

Veradermics, Incorporated (MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on pattern hair loss, reported a net loss of $21.0 million for the third quarter of 2026, compared with a net loss of $20.1 million a year earlier.

After quarter-end, the company disclosed positive topline results from two male pattern hair loss trials that had been flagged only as anticipated in the second-quarter release. Phase 3 Study ‘304’ Part A met all primary and secondary endpoints, and 12-month data from Phase 2/3 Study ‘302’ showed continued hair growth in the VDPHL01 continued group.

Chief Executive Officer Reid Waldman, M.D., said the year had been defining as the company advanced VDPHL01 in both men and women, citing more than 1,000 male participants across Studies ‘302’ and ‘304’ and early, consistent, and robust hair growth. He said the company remains well capitalized to continue development and advance preparations for a potential commercial launch.

In October 2026, Veradermics announced that Part A of Study ‘304’ met all primary and secondary endpoints with high statistical significance. Among participants who received VDPHL01 8.5 mg once or twice daily for six months, mean increases in non-vellus target area hair count were 36.4 hairs/cm² (twice daily) and 28.6 hairs/cm² (once daily) at Month 6. Sixty-eight point seven percent of twice-daily participants and 55.7 percent of once-daily participants achieved ‘improved’ or ‘much improved’ hair coverage on the Androgenetic Alopecia Impact Rating Scale at Month 6. The company said no treatment-related serious adverse events and no adverse events of special interest of cardiac origin were observed.

In November 2026, the company reported 12-month results from Study ‘302’. Among participants who continued VDPHL01 8.5 mg twice or once daily, mean increases in non-vellus target area hair count were 43.9 hairs/cm² (twice daily) and 29.7 hairs/cm² (once daily) at Month 12. Eighty-nine point one percent of twice-daily continued participants and 79.8 percent of once-daily continued participants reported visible improvement in hair coverage on the AAIRS at Month 12. Sixty-eight point zero percent of twice-daily participants and 48.4 percent of once-daily participants achieved ‘improved’ or ‘much improved’ coverage. Treatment was generally well tolerated through Month 12, with no treatment-related serious adverse events, no cardiac adverse events of special interest, and no new safety signals.

Placebo-crossed arms in Study ‘302’ showed mean non-vellus hair count increases of 32.1 hairs/cm² (twice-daily crossed) and 24.5 hairs/cm² (once-daily crossed).

Female development remained on the same timeline already disclosed in the second-quarter release. Study ‘207’, an open-label Phase 2 trial, had shown rapid onset and consistent hair growth in women. Enrollment in Study ‘306’, a 556-participant registration-directed Phase 2/3 trial, was completed in August 2026. The company expects topline data from Study ‘306’ in the first half of 2027.

Research and development expenses were $16.1 million for the quarter ended September 30, 2026, down $2.0 million from $18.1 million a year earlier. The company said the decrease was primarily due to lower clinical development and other development expenses of VDPHL01, partly offset by higher payroll, including $0.8 million more stock-based compensation.

General and administrative expenses were $12.7 million, up $10.5 million from $2.3 million a year earlier. The company attributed the increase to higher payroll, including $3.1 million more stock-based compensation, plus additional commercial readiness costs and other professional fees.

Interest income was $5.1 million for the three months ended September 30, 2026, versus $71 thousand a year earlier. Other income was $2.7 million, versus $174 thousand.

Cash, cash equivalents and marketable securities totaled $798.4 million as of September 30, 2026, down from $819.9 million as of June 30, 2026. The company said that cash position is expected to fund operations into 2030 through multiple Phase 3 readouts and a potential commercial launch of VDPHL01.

VDPHL01 is an investigational oral extended-release minoxidil tablet. The company said that, if approved, it would be the only FDA-approved oral non-hormonal treatment for pattern hair loss in both male and female patients, and that the earliest expiring patent term is 2043.